Startup accelerator Bluepoint Partners announced on the 7th that it is recruiting teams to participate in the bio·healthcare investment-linked program 'Watson 121'.
'Watson 121' is a program aimed at prospective and early-stage entrepreneurs in the bio·healthcare sector. Professional evaluators from Bluepoint's biohealthcare team, the 'Watson Team,' work closely on a one-on-one basis to review the current business status and provide guidelines to build a foundation for growth. The recruitment target is prospective startup teams with two or more members or early-stage startup teams within three years of establishment across all fields of bio·healthcare. The application period is until the 4th of next month.
In particular, the 'Watson 121' program is expected to be helpful for early-stage companies preparing for TIPS and Deep Tech TIPS, support projects by the Ministry of SMEs and Startups. These companies can review their growth roadmap for TIPS selection and receive customized support through the program. Additionally, the Watson Team's expertise and network in new drug development, medical devices, medical artificial intelligence, and regulatory affairs enable multifaceted support for prospective and early-stage startup teams.
Bluepoint holds investment expertise in this field, with bio·healthcare companies accounting for about 20% of its entire investment portfolio. More than 70 companies, including Plasmapp and Inventi Labs, which successfully went public on the KOSDAQ market last year, are creating excellent growth cases.
Park Soo-yong, senior evaluator of Bluepoint's Watson Team, said, "Although the funding environment in the bio·healthcare sector is still challenging, companies with solid business preparation are achieving steady growth," adding, "Through this program, we will support teams with a strong will to grow based on Bluepoint's bio·healthcare growth model."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
